Purchase of Ordinary Shares

RNS Number : 8768N
Judges Scientific PLC
06 June 2022
 

Press Release

 

 

 

Judges Scientific plc

 

("Judges Scientific" or the "Company")

 

Purchase of Ordinary Shares

 

Judges Scientific announces that it has today acquired 1,036 ordinary shares of 5p each ("Ordinary Share") at a price of 8,150p per Ordinary Share. The Ordinary Shares have been immediately allocated to certain employees to satisfy awards under the Company's reward scheme.

 

Ends -  

For further information please contact:

Judges Scientific

 

 

David Cicurel, CEO

Brad Ormsby, Group FD

Tel: +44 (0) 20 3829 6970


 

Shore Capital (Nominated Adviser & Broker)


Stephane Auton

Iain Sexton

Tel: +44 (0) 20 7408 4090

 

Liberum (Joint Broker)

Edward Mansfield

William Hall

 

Media enquiries:

Alma PR (Financial Public Relations)

 

Tel : +44 (0) 20 3100 2222

 

Sam Modlin

Justine James

Joe Pederzolli

 

Tel: +44 (0) 20 3405 0205

judges@almapr.co.uk

 

Notes to editors:  

Judges Scientific plc (AIM: JDG), is a group focused on acquiring and developing companies in the scientific instrument sector.  The Group now consists of 20 businesses acquired since 2005.

The acquired companies are primarily UK-based with products sold worldwide to a diverse range of markets including: higher education institutions, scientific research facilities, manufacturers and regulatory authorities.  The UK is a recognised centre of excellence for scientific instruments.  The Group has received five Queen's Awards for innovation and export.

The Group's companies predominantly operate in global niche markets, with long term growth fundamentals and resilient margins.

Judges Scientific maintains a policy of selectively acquiring businesses that generate sustainable profits and cash.  Shareholder returns are created through the reduction of debt, organic growth and dividends.

For further information, please visit  www.judges.uk.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSUPUQAQUPPGWQ
UK 100

Latest directors dealings